Venable enjoyed another great conference at SupplySide West 2019. Hot topics included such ingredients as collagen, probiotics, and, of course, the ever-popular CBD. Across the industry, innovation is moving full-speed ahead as companies are finding new ways to deliver these ingredients and highlight their potential health benefits. For CBD, we are seeing new product categories, such as candies and gum. The CBD market is also expanding into the sports nutrition space to highlight the potential benefits to recovery and cognitive performance. In addition, companies are focusing their claims on the specific type of CBD, identifying cannabinoid contents and other strain-specific attributes. We are seeing the same strain-specific focus in the probiotic space. Companies are homing in on potential benefits aside from gut health, including cognitive health and athletic performance. Collagen has been a popular ingredient over the past few years, and we are now seeing more conventional food forms of collagen products, such as beverages and snack foods. Also of note, the focus on mindful nutrition was prevalent, as companies are increasing the transparency of ingredients on product labeling to appeal to consumer preferences. Ingredient quality and source claims continue to be common, as do claims highlighting the absence of certain ingredients.
Our Speaking Engagements
FSMA and Import Requirements for Food and Supplement Brands
Wednesday, October 16 | 9:00 am - 12:00 pm
The Food Safety Modernization Act (FSMA) brought sweeping legislation designed to improve food safety for Americans, with new authority for FDA, requirements for foreign imports, and a shift toward prevention rather than response. Visitors explored what the law requires, how to implement its requirements, and where companies are falling short.
Business of CBD in Food & Beverages
Saturday, October 19 | 8:30 am - 11:30 am
A market look at players in the food/beverage industry and specific related cannabis applications. Massive players in the F&B space are starting to invest in cannabis/CBD as regulators liberalize their policies—led by Constellation Brands with its $4 billion investment in Canopy Growth. What are the opportunities and challenges?